FDA approves CSL Behring genetic bleeding disorder drug Corifact
Patients with congenital Factor XIII do not make enough Factor XIII, a substance in the blood that is important for normal clotting, and people with this condition are
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.
Apart from eyeing OTC brands across vitamins, mineral supplements, orthopaedic, gynaecology and nutraceutical brands, Sanofi Aventis is also looking for brands in anti-infective, antibiotics, respiratory tract infection and
Eliglustat tartrate is a novel glucosylceramide analog administeredorally, which partially inhibits the enzyme glucosylceramide synthase. Currently, it is being developed to provide a convenient treatment alternative for adult